Receive The Newest Study Notifications

Multicenter, Randomized ONSET-2 Study Will Evaluate OC-01 as Novel Option for Common Eye Condition Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical...

The Alzheimer's Association has awarded Longeveron LLC, a Miami-based biopharmaceutical company that develops cellular therapies for aging-related diseases, a $3 million grant to be applied to the company's mesenchymal stem cell Alzheimer's research. The prestigious...

Veristat, a scientifically oriented clinical development, and regulatory submission partner, announces the formal launch of its Clinical Trial, Biostatistics and Programming operations in Taipei, Taiwan with the opening of a new office. “The growth of Veristat’s...

 Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, with Australia being the...

 PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of...

- Designed to overcome barriers to testing and connect patients to earlier diagnosis and treatments - - Targeting diagnosis of muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases - SAN FRANCISCO, July 24, 2019 /PRNewswire/...

ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted in fourth quarter of 2019 BLUE BELL, Pa., July...

- Milciclib was well tolerated and no drug related deaths were reported 28 out of 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing...

CytRx Corporation(OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evaluating arimoclomol for the...

July 22, 2019 11:00 UTC Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR...

 Salarius Pharmaceuticals, Inc.(Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has enrolled the first patient in a Phase 1 clinical study of the company’s lead compound, Seclidemstat, in patients with...

Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food & Drug Administration (FDA) on...

A research group in Lund led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells. Further experiments and studies have shown that the effect is due to the most common protein...

Globalization has had a definitive impact on nearly every industry, and, in recent years, its effects on the clinical trials industry have become apparent. Clinical trials are necessary for public health in every society, developed and developing alike, and the...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that enrollment in the T2 Protect...

FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). “There is an urgent need for new treatments that will help IPF patients, who have...

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's investigational new drug,...

Unites Four of the Top US Clinical Research Facilities to Reduce Time and Cost for New Drug Development CenExel Clinical Research, Inc., ("CenExel" or the "Company") announces the creation of their Centers of Excellence company, which unites four of the most...

-- Administration procedure designed to optimize physician and patient experience and convenience -- -- Company also shares interim analysis of 719 patients in VICTORY-3 Phase 3 open-label trial indicating the studied streamlined administration procedures maintain...

These next-generation SPEAR T-cells may improve long term T-cell functions PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (ADAP), a leader in T-cell therapy to treat...